OLE Study to Evaluate Safety / Efficacy of ZD4522
Information source: AstraZeneca
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Hypercholesterolaemia
Intervention: Rosuvastatin (Drug)
Phase: Phase 3
Status: Completed
Sponsored by: AstraZeneca Official(s) and/or principal investigator(s):
Elinor Miller, MD, Study Director, Affiliation: AstraZeneca
Summary
The purpose of this study is to assess the long term safety of Crestor.
Clinical Details
Official title: ZD4522 Long Term Extension Trial
Study design: Treatment, Non-Randomized, Open Label, Single Group Assignment, Safety/Efficacy Study
Primary outcome: Safety, as determined by adverse events, laboratory data, physical examination and ECG.
Secondary outcome: Success in achieving goals for Cholesterol levels
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Completion of previous Crestor study as listed in the protocol.
Exclusion Criteria:
- Pregnant or breast feeding women, or not using appropriate contraception.
- Abnormal lab values as listed in the protocol.
Locations and Contacts
Additional Information
Starting date: August 1999
Ending date: June 2005
Last updated: April 2, 2008
|
